# www.tempus.com

> AI-optimized mirror of www.tempus.com containing 50 pages totalling 26,802 words of clean markdown content, structured data, and semantic HTML. Original source: https://www.tempus.com/. Last updated: 2026-04-25T20:23:54.253Z.

Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG).

## Homepage

- [AI-enabled   precision medicine](/site-root.html): Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer. (746 words)

## Articles & Blog Posts

- [RWD & Tempus Lens](/image-recognition/index.html): Access Tempus’ library of de-identified, multimodal real-world data (RWD) through our Lens platform or data collaboration partnerships to power your research. (1,033 words)
- [Genomic and Transcriptomic Mediators of Resistance to Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (MBC): A Comprehensive Multi-Center Study](/publications/genomic-and-transcriptomic-mediators-of-resistance-to-antibody-drug-conjugates-adcs-in-metastatic-breast-cancer-mbc-a-comprehensive-multi-center-study.html) (505 words)
- [products-services/index.html](/products-services/index.html) (1 words)
- [Do we have the technology to cure pancreatic cancer?](/news/do-we-have-the-technology-to-cure-pancreatic-cancer.html) (897 words)
- [Association Between LAG3 Expression and Immune Checkpoint Inhibitor (ICI) Efficacy in Advanced Melanoma](/publications/association-between-lag3-expression-and-immune-checkpoint-inhibitor-ici-efficacy-in-advanced-melanoma.html) (471 words)
- [Tempus Unveils A Breakthrough in AI for Oncologists: Tempus ONE](/news/pr/tempus-unveils-a-breakthrough-in-ai-for-oncologists-tempus-one.html) (525 words)
- [Tempus Announces Expansion Into Infectious Diseases, Starting with COVID-19](/news/pr/tempus-announces-expansion-into-infectious-diseases-starting-with-covid-19.html) (572 words)
- [Tempus and Yale Announce Research Collaboration to Accelerate COVID-19 Test Development](/news/pr/tempus-and-yale-announce-research-collaboration-to-accelerate-covid-19-test-development.html) (592 words)
- [Investigating the Clinical Landscape and Biological Impact of SF3B1 Hotspot Mutations in Breast Cancer](/publications/investigating-the-clinical-landscape-and-biological-impact-of-sf3b1-hotspot-mutations-in-breast-cancer.html) (444 words)
- [Clinical Breast Cancer Study Reveals that Tempus’ Real-World Database Mirrors Overall U.S. Breast Cancer Population](/news/pr/clinical-breast-cancer-study-reveals-that-tempus-real-world-database-mirrors-overall-u-s-breast-cancer-population.html) (489 words)
- [test-live-homepage/index.html](/test-live-homepage/index.html) (1 words)
- [Smoking has a very broad, long-lasting impact on the human genome](/news/smoking-has-a-very-broad-long-lasting-impact-on-the-human-genome.html) (575 words)
- [Genetic and Clinical Landscape of NUTM1 Structural Variants](/publications/genetic-and-clinical-landscape-of-nutm1-structural-variants.html) (489 words)
- [Functional Precision Medicine: Uncovering High Actionability in Rare Cancers Beyond Genomics](/publications/functional-precision-medicine-uncovering-high-actionability-in-rare-cancers-beyond-genomics.html) (502 words)
- [Visium HD Combined With Deep-Learning-Based Cell Segmentation on H&E Images Yield Accurate Cell Annotation at Single-Cell Resolution](/publications/visium-hd-combined-with-deep-learning-based-cell-segmentation-on-he-images-yield-accurate-cell-annotation-at-single-cell-resolution.html) (389 words)
- [Stratification of Cell Therapies in Solid Tumor Organoids Using Deep Learning-Derived Imaging Metrics](/publications/stratification-of-cell-therapies-in-solid-tumor-organoids-using-deep-learning-derived-imaging-metrics.html) (454 words)
- [Tempus Expands Licensing Agreement with Bristol Myers Squibb to Analyze and Discover RNA-Based Targets](/news/pr/tempus-expands-licensing-agreement-with-bristol-myers-squibb-to-analyze-and-discover-rna-based-targets.html) (353 words)
- [Tempus Announces Glioblastoma Data Offering in Collaboration with ASCO](/news/pr/tempus-announces-glioblastoma-data-offering-in-collaboration-with-asco.html) (394 words)
- [Identification of Predictive Biomarkers of Response to ADCs by HTS of Highly Molecularly Characterized Panels of Patient-Derived Organoids (PDOs)](/publications/identification-of-predictive-biomarkers-of-response-to-adcs-by-hts-of-highly-molecularly-characterized-panels-of-patient-derived-organoids-pdos.html) (437 words)
- [Tempus Announces the Appointment of Nobel Laureate and CRISPR Co-Inventor, Dr. Jennifer Doudna, to its Board of Directors](/news/pr/tempus-announces-the-appointment-of-nobel-laureate-and-crispr-co-inventor-dr-jennifer-doudna-to-its-board-of-directors.html) (429 words)
- [Tempus Signs Strategic Collaboration Agreement with AstraZeneca to Advance Oncology Therapeutics](/news/pr/tempus-signs-strategic-collaboration-agreement-with-astrazeneca-to-advance-oncology-therapeutics.html) (378 words)
- [Tempus Announces $200 Million Series G-2 Financing](/news/pr/tempus-announces-200-million-series-g-2-financing/index.html) (395 words)
- [FAQ](/patient/index.html) (480 words)
- [Providers](/applications/index.html): Tempus can help physicians & healthcare providers make more informed treatment decisions, and provides opportunities for research collaborations. Learn more. (182 words)
- [resources/content/articles/the-value-of-rna-sequencing-in-drug-discovery/index.html](/resources/content/articles/the-value-of-rna-sequencing-in-drug-discovery/index.html) (1 words)
- [Demo Video](/demo-video/index.html) (23 words)
- [Tempus ONE Download](/tempus-one-download/index.html) (7 words)
- [resources/content/articles/how-ai-impacts-clinical-trial-process-design-matching.html](/resources/content/articles/how-ai-impacts-clinical-trial-process-design-matching.html) (1 words)
- [Case Study Download - Tempus](/case-study-download/index.html) (7 words)
- [Tempus Reports Fourth Quarter and Full Year 2025 Results](/news/pr/tempus-reports-fourth-quarter-and-full-year-2025-results.html): Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2025. (2,795 words)
- [NEWS](/news/pr/index.html): Search and view all Tempus press releases. (736 words)
- [Computational power limits oncology innovation: Here’s why](/resources/content/articles/computational-power-limits-oncology-innovation-heres-why.html) (1,208 words)
- [Tempus notetaker](/neurology-psychiatry/notetaker/index.html): Discover Tempus Notetaker, an AI-powered solution that listens to patient-clinician conversations and automatically generates clinical notes for review. (905 words)
- [Tempus Team Members](/team_members-sitemap-xml.html) (114 words)
- [Tempus Completes Acquisition of Ambry Genetics](/news/acquisition-of-ambry-genetics/index.html) (845 words)
- [LIFE SCIENCES /// CLINICAL DEVELOPMENT](/life-sciences/clinical-development/index.html): Accelerate your clinical development with Tempus. We offer solutions for trial design, patient enrollment, and companion diagnostic development. (619 words)
- [Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine](/news/pr/tempus-and-usc-announce-strategic-collaboration-to-accelerate-ai-driven-precision-medicine.html) (1,018 words)
- [Illumina and Tempus Partner to Drive the Future of Precision Medicine Through Genomic AI Innovation](/news/illumina-and-tempus-partner-to-drive-the-future-of-precision-medicine-through-genomic-ai-innovation.html) (1,219 words)
- [We are a team with a singular shared goal: to improve patient outcomes.](/about-us/our-team/index.html): Our team has a breadth of expertise, and together, we attack cancer from every direction. Learn more about our leaders, directors, and scientific advisors. (515 words)
- [Unveiling Integrin Beta-6 (IB6): Real-World Data From the IB6 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer Study](/publications/unveiling-integrin-beta-6-ib6-real-world-data-from-the-ib6-expression-and-clinical-outcomes-in-non-small-cell-lung-cancer-study.html) (375 words)
- [Eric Lefkofsky](/team_members/eric-lefkofsky/index.html) (165 words)
- [Get to know us better](/about-us/careers/index.html): Join Tempus and help advance precision medicine. Explore open roles in engineering, research, clinical operations, and more to build the future of healthcare. (189 words)
- [Our History](/about-us/our-history/index.html): Learn about the history of Tempus, founded in 2015 by Eric Lefkofsky to bring the power of data and artificial intelligence to precision medicine. (199 words)
- [post-sitemap-xml.html](/post-sitemap-xml.html) (2,165 words)
- [biomarker-sitemap-xml.html](/biomarker-sitemap-xml.html) (64 words)
- [post-sitemap2-xml.html](/post-sitemap2-xml.html) (1,452 words)
- [page-sitemap-xml.html](/page-sitemap-xml.html) (372 words)
- [indication-sitemap-xml.html](/indication-sitemap-xml.html) (36 words)
- [Application error: a client-side exception has occurred while loading www.tempus.com (see the browser console for more information).](/oncology/index.html): For oncology providers, our suite of precision oncology solutions deliver a comprehensive view of your patients & allow you to customize treatment. Learn more. (39 words)

## Resources

- [Full Page Index](/index.html): Browse all cached pages with rich metadata
- [About This Cache](/content/about.html): Methodology, technical details, and usage guidelines
- [XML Sitemap](/content/sitemap.xml): Machine-readable sitemap for crawler discovery
- [Robots.txt](/content/robots.txt): Crawler directives